{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ambros IM"],"funding":["Cancer Research UK","NCI NIH HHS"],"pagination":["3685-3697"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7605396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["38(31)"],"pubmed_abstract":["<h4>Purpose</h4>For localized, resectable neuroblastoma without <i>MYCN</i> amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome.<h4>Patients and methods</h4>Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) Biology Group.<h4>Results</h4>Patients with stage 1 tumors had an excellent "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group."],"pmcid":["PMC7605396"],"funding_grant_id":["23804","U10 CA180886","U10 CA180899"],"pubmed_authors":["Bown N","Couturier J","Van Roy N","Schleiermacher G","Beiske K","Kogner P","Valent A","Defferrari R","Castel V","Mazzocco K","De Bernardi B","Tweddle DA","Berbegall AP","Lunec J","Marques B","Combaret V","Villamon E","Martinsson T","Mosseri V","Benard J","Ladenstein R","Valteau-Couanet D","Monclair TF","Noguera R","Glogova E","Holmes K","Cohn S","Gross N","Janousek D","Pearson ADJ","Ambros PF","Michon J","Hogarty MD","Park JR","Jeison M","Potschger U","Attiyeh EF","Beck-Popovic M","Tonini GP","Ambros IM","Caron H","Pribill I","Delattre O"],"additional_accession":[]},"is_claimable":false,"name":"Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.","description":"<h4>Purpose</h4>For localized, resectable neuroblastoma without <i>MYCN</i> amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome.<h4>Patients and methods</h4>Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) Biology Group.<h4>Results</h4>Patients with stage 1 tumors had an excellent ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-05-29T19:01:14.203Z","creation":"2022-02-11T12:21:15.342Z"},"accession":"S-EPMC7605396","cross_references":{"pubmed":["32903140"],"doi":["10.1200/JCO.18.02132"]}}